Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of ARA 290 in sarcoidosis-associated neuropathic pain
NL-OMON38804Phase 2Active, not recruiting
- Sponsor
- Araim Pharmaceuticals
- Start
- Nov 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cibinetide in sarcoidosis, small fiber neuropathy (SFN) and Neuralgia (4 arms), sponsored by Araim Pharmaceuticals. Primary endpoint: Change in corneal nerve fiber density. Started Nov 2013; status: active, not recruiting.
02
Drugs
cibinetide
03
Conditions
sarcoidosissmall fiber neuropathy (SFN)Neuralgia
Beyond the preview
Go deeper on NL-OMON38804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38804.